Myeloproliferative neoplasia (MPN)-associated pulmonary hypertension (PH) is included in group five of the most recent clinical classification of PH.
A 69-year-old woman with a ten-year history of JAK2 p.V617F-positive polycythemia vera presented with a twoyear history of progressive exertional dyspnea. On physical exam, her vital signs were normal. She had holosystolic murmur over the tricuspid area, scattered ecchymosis over limbs, and tender splenomegaly.
Her polycythemia vera was treated with hydroxyurea (500 mg daily) and later with Peg-interferon alpha (90 mcg weekly for eight months). However, she continued to experience worsening thrombocytopenia and tender splenomegaly. A bone marrow biopsy showed changes of postpolycythemic myelofibrosis. She was started on ruxolitinib (15 mg twice daily) along with prednisone (dose range of 15-25 mg daily). Her tender splenomegaly and functional status initially improved. However, six months later, she experienced worsening exertional dyspnea. A ventilationperfusion (VQ) scan showed very low probability for pulmonary embolism and chest CT showed diffuse bilateral ground glass opacities (GGOs) (Fig. 1a) . A T C M-labeled colloid scan showed no evidence of EMH. Surgical lung biopsy of the left lower lobe showed an interstitial pneumonitis-like EMH (Fig. 1b-d) . Single fraction whole-lung radiation was initiated (1000 cGY). Her ruxolitinib was held for six weeks because of worsening anemia and thrombocytopenia from radiation therapy. During this period, repeat echocardiogram was unchanged from four months prior. Her ruxolitinib was restarted following improvement in her cell counts. However, she continued to experience worsening exertional dyspnea. Repeat chest CT demonstrated progressive bilateral GGOs. A bronchoscopy with broncho-alveolar lavage (BAL) of the right middle lobe ruled out infection. A repeat echocardiogram study showed severely dilated right ventricle with severe PH. A subsequent right heart catheterization (RHC) demonstrated moderate pre-capillary PH (Table 2) . She was started on sildenafil (20 mg three times daily). However, despite initial improvement in her dyspnea, she died several months later.
Case 2
A 72-year-old man with JAK2 p.V617F-positive secondary myelofibrosis was referred for bronchoscopy following an abnormal chest radiograph as part of pre-allogeneic stem cell transplant workup. Review of systems was notable for increasing fatigability and dyspnea on exertion over the past few months.
He was diagnosed with JAK2-positive polycythemia vera 25 years ago. He was treated with hydroxyurea (500 mg daily), Peg-interferon alpha (135 mcg weekly), and imatinib (300 mg daily). Despite this, he continued to have worsening anemia, thrombocytopenia, and increasing tender splenomegaly. He was ultimately switched to ruxolitinib (20 mg in the morning and 15 mg at night) and 6-mercaptopurine (50 mg three times a week). However, he remained transfusion dependent and the decision was made to proceed with allogeneic stem cell transplantation.
On presentation, his vital signs were normal. On exam, he had scattered ecchymosis over his upper limbs and trunk, and tender splenomegaly. Initial investigations were notable for leukocytosis of 40.7 Â 10 3 /uL (with 39% neutrophils, 7% lymphocytes, 13% myelocytes, 5% basophils), hemoglobin of 7.8 g/dL, and platelet count of 40 Â 10 3 /uL. Chest X-ray demonstrated right greater than left peri-hilar opacity and chest CT showed bilateral patchy foci of GG attenuation with associated interlobular septal thickening (Fig. 2a) . Subsequent bronchoscopy demonstrated bloody secretions in bilateral airways with no active bleeding. BAL aliquots of right upper and medial lobes returned progressively bloodier consistent with diffuse alveolar hemorrhage. The microbiologic analysis of the BAL was negative for infection. A surgical lung biopsy of the right upper lobe was then performed. This showed multi-focal EMH and pulmonary arteriopathy with medial thickening (Fig. 2b and c). The patient also had an echocardiogram performed that demonstrated moderate PH with normal right ventricular function and size. A subsequent RHC demonstrated mild pre-capillary PH ( Table 2 ).
The patient is currently awaiting pre-allogeneic stem cell transplantation induction therapy with decitabine.
Case 3
A 63-year-old woman with a history of JAK2 p.V617F-positive secondary myelofibrosis presented with a twoweek history of fevers, chills, and productive cough of yellow sputum. Review of systems was notable for a twoyear history of increasing lethargy, worsening exertional dyspnea, and non-productive cough. Her past medical history was notable for polycythemia vera diagnosed at age 36 years which evolved into secondary myelofibrosis three years ago. She has been on several different therapies including hydroxyurea, danazol, thalidomide, and elotuzumab. Over the past one year she had been on a clinical trial drug, CYT 387.
On admission, her temperature was 39.2 C, heart rate 101 bpm, blood pressure 121/67 mmHg, oxygen saturation 97% breathing ambient air, and respiratory rate of 16 breaths/min. Physical exam was notable for scattered ecchymosis over her trunk and limbs, and tender splenomegaly. Initial investigation was notable for increasing leukocytosis of 19.1 Â 10 3 /uL (3 months prior: 9.7 Â 10 3 /uL) with 35% neutrophils, hemoglobin of 10.7 g/dL, and platelet count of 66 Â 10 3 /uL (3 months prior 28 Â 10 3 /uL). Admission chest X-ray demonstrated interval development of patchy air-space opacity in the lingula. She was treated for suspected pneumonia with ceftriaxone and azithromycin. She also had a bronchoscopy with BAL of the lingula. The BAL study was negative for infection. She was discharged and had a brief period of clinical improvement following completion of her antibiotic course. However, she re-presented several weeks later with two episodes of scant hemoptysis. A repeat chest CT showed diffuse nodular interstitial thickening with a few small consolidative areas (Fig. 3a) . Repeat bronchoscopy did not demonstrate bleeding or infection. A surgical lung biopsy of the right lower lobe showed intra-pulmonary histiocytoid Sweet's syndrome with a component of EMH (Fig. 3b and c) . At this juncture, she was commenced on prednisone.
Approximately six months later, her secondary myelofibrosis transformed into acute myeloid leukemia. Her investigational drug was discontinued and she was treated initially with hydroxyurea and later with decitabine.
However, her cough and exertional dyspnea continued to worsen and repeat chest CT demonstrated new patchy consolidations of the right upper and left lower lobes. An echocardiogram performed showed mild PH with normal right and left ventricular size and function (Table 2) . She continued to decline clinically and died soon after.
Discussion
Most cases of EMH are tied to underlying chronic MPN or hemoglobinopathies such as thalassemia and sickle cell anemia. EMH commonly involves the liver and spleen but may occur in the lungs, pleura, lymph nodes, urogenital system, and in the para-spinal or epidural spaces. 3 Intrapulmonary involvement is rare, with approximately 40 cases described. 4 The pathogenesis of pulmonary EMH is poorly understood. It may represent differentiation of embryonic hematopoietic stem cells or the abnormal release of marrow precursors into the circulation. The latter is supported by the 400Â increase in number of circulating CD34þ hematopoietic precursor cells in patients with primary myelofibrosis. This forces the expansion of hematopoietic tissue in areas other than the liver and spleen. 5 Chest CT is the main imaging modality in the evaluation of pulmonary EMH, though findings are non-specific. Prior case reports demonstrate varied imaging appearances, which include pulmonary nodules and masses, consolidations, septal line thickening, and pulmonary fibrosis. 6 Nodules can be solitary or multiple, bilateral or unilateral, and calcified or non-calcified. 3 In the three cases presented above, the predominant findings are interlobular septal thickening and GGOs. These two findings are superimposed in one case, a combination commonly referred to as the ''crazy paving'' sign. While one case demonstrates innumerable 1-2 mm interstitial nodules, none depict larger nodules or masses, and there is no example of pulmonary fibrosis. To our knowledge, these are the first cases of pulmonary EMH with GGOs, which probably correspond to the histologic finding of intra-lobular septal thickening. These microscopic septa are below the resolution of CT and imperceptible when normal. When thickened, the aggregate appearance is GG attenuation rather than multiple discrete lines, unlike thickened interlobular septa, which are larger and clearly linear. In the setting of thrombocytopenia, alveolar hemorrhage may contribute to GGOs. In areas of more focal or profuse hemorrhage, small consolidations may be present. In case 2 depicting the ''crazy paving'' sign, the main diagnostic consideration prior to biopsy was secondary pulmonary alveolar proteinosis, which is also associated with myelodysplastic syndrome. 7 The most common site of EMH in the thorax is the posterior mediastinum. 8 Solitary or multilevel para-spinal masses, with or without fat, are seen in several causes of chronic anemia. The presence of para-spinal masses would lend support to a diagnosis of pulmonary EMH with the appropriate findings; however, there was no posterior mediastinal involvement in our three cases. Pleural EMH is considered particularly rare and also was not present. 8 In addition to standard chest CT, radionuclide imaging can be used to detect sites of EMH using radiotracers that normally distribute in bone marrow. Technetium-99 m sulfur colloid and technetium-99 m anti-CD66 monoclonal antibody have both demonstrated pulmonary uptake in the presence of EMH. 9 False negatives occur if there is little medullary stroma present or if there is low cell activity. 5 There are several pathophysiologic mechanisms implicated in the development of PH in patients with MPN (Table 1) . 10 Drugs that have been implicated with PH include anagrelide, 10 ruxolitinib, 11 dasatinib, 1 and interferon alpha. 12 Dasatinib and interferon therapy are regarded as likely and possible causes of PH, respectively. 1 Ruxolitinib, a selective JAK1 and 2 inhibitor, improves splenomegaly, disease-related symptoms, and quality of life in patients with myelofibrosis. 13 There has been a single case report implicating ruxolitinib with worsening PH in a patient with JAK2 p.V617F-positive idiopathic myelofibrosis. The patient developed worsening exertional dyspnea two and six weeks following ruxolitinib commencement with subsequent symptomatic and echocardiographic improvement on withdrawal of the drug on two separate occasions. 11 Our patient in case 1 developed worsening exertional dyspnea six months after starting ruxolitinib. The development of her PH coincided with worsening leukocytosis and radiographic progression of disease. Furthermore, there was lack of echocardiographic improvement following ruxolitinib cessation. The lack of echocardiography (TTE) prior to initiation of ruxolitinib is a limitation in case 2. However, the onset of his symptoms was about two years following ruxolitinib and coincided with radiographic evidence of disease. Peg-interferon alpha therapy is unlikely to be the cause of PH in our patients. The patients in cases 1 and 2 did not have the usual co-morbidities seen with interferon therapy-associated pulmonary arterial hypertension (PAH), such as chronic hepatitis C or HIV co-infection. 12 Furthermore, they were off their Peg-interferon alpha treatment for more than one year prior to their symptom onset and PH progression. The true presence of pulmonary hypertension in case 3 is uncertain owing to the absence of RHC data. The echocardiogram in case 3 showed mild PH with a normal right ventricular size and function. Studies that use TTE as the primary diagnostic tool are hampered by inaccuracies leading to frequent over-or under-estimation of true right ventricular systolic pressure [14] [15] [16] [17] and are also discordant from the gold standard, RHC findings.
18 Table 2 summarizes the chest CT features, pathological findings, echocardiographic, and RHC data of our three patients.
On a molecular level, aberrancy in the Janus Kinase (JAK)/Src -Signal Transducer and Activator of Transcription 3 (JAK/Src-STAT3) signaling pathway may also contribute to the pathogenesis of PH in myelofibrosis ( Table 2 ). All three patients with polycythemia vera had JAK2 p.V617F mutation and later developed myelofibrosis. JAK-2 expression has been demonstrated in limited cutaneous sclerosis-associated PAH but not in idiopathic PAH. 19 Increase in Src and Src-related proteins are found in PAHpulmonary arterial smooth muscle cells (PASMC) and in hypoxia and monocrotaline experimental models of PAH. 20 Src and JAK proteins phosphorylate and activate STAT3 protein in response to various cytokines. 21 These cytokines, which include endothelin-1, angiotensin II, 22 and platelet-derived growth factor (PDGF), 23 are commonly implicated in the pathogenesis of PAH. The increased and sustained STAT3 phosphorylation potentially contributes to pulmonary hypertension by promoting abnormal vascular endothelial cell hyper-proliferation, 24 by promoting inflammation 21 and angiogenesis, 21 and by depleting pulmonary vascular endothelial cells (PAECs) nitric oxide stores. 25 In idiopathic PAH patients, increased numbers of activated STAT3 are seen in plexiform lesions, intimal lesions, and in the endothelium of small pulmonary arteries. Inhibition of STAT3 phosphorylation was shown to reduce the proliferation of PAECs in these lesions. 24 Meanwhile, inhibition of JAK-1 and JAK-2 by ruxolitinib increases NO levels and improves serum biomarkers of PH in patients with myelofibrosis and echocardiographic evidence of PH. This increase in NO is related to the increase in NO-inducing cytokine (IFN-gamma) and reduction in NO-inhibiting cytokines (TNF, IL-4, and IL-10). 25 However, the use of other tyrosine kinase inhibitors (TKI) in PH has yielded mixed results. Dasatanib has been implicated as a likely cause of drug-induced PH. 1 Imatinib was shown to improve pulmonary hemodynamics and exercise capacity in patients with idiopathic PAH. 26 The exact mechanism of dasatinib-induced PH is not well understood. Among patients with dasatinib-induced PH, those given nilotinib following dasatinib discontinuation did not develop disease recurrence. This suggests that dasatinibinduced PH is perhaps a specific complication of dasatinib use rather than a TKI-class related effect. 27 There is also increasing evidence supporting the role of myeloid cells in the pathogenesis of PAH. [28] [29] [30] [31] The three patients had myeloid metaplasia, and myeloid hematopoietic precursors occupied the pulmonary interstitium and showed vasculocentricity. In patients with idiopathic PAH, there is an increase in myeloid progenitor cell accumulation in the remodeled pulmonary arteries. 29 Recently, Yan et al. demonstrated that control mice transplanted with bone marrow that expressed the BMPR2 R899X mutation developed neo-muscularization of the pulmonary vasculature, while engraftment of BMPR2 R899X transgenic mice with control bone marrow attenuated PH development. 31 These studies suggest that myeloid cells play a key role in the pathogenesis of PH.
Conclusion
Pulmonary EMH in myelofibrosis with resulting PH is a rare clinical entity. Our series expands on prior reports and demonstrates consistent clinical-pathologic-radiological correlates useful to clinicians and pathologists in their assessment of patients with MPN who present with pulmonary symptoms suggestive of EMH. The treatment of chronic MPN-associated PH should be directed towards the underlying cause. When PH is diagnosed, associated conditions such hypoxia, anemia, and heart failure should be treated in conjunction with appropriate cyto-reductive agents. PH-specific pharmacotherapy should be reserved for patients who continue to demonstrate exhausted cardio-pulmonary reserve despite conventional therapies. Unfortunately, the prognosis of patients with chronic MPN-associated PH remains poor with a median survival time of 18 months.
